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Abstract—Aortic stenosis is the most frequent valvular heart disease. In aortic stenosis, therapeutic decision essentially 
depends on symptomatic status, stenosis severity, and status of left ventricular systolic function. Surgical aortic valve 
replacement or transcatheter aortic valve implantation is the sole effective therapy in symptomatic patients with severe 
aortic stenosis, whereas the management of asymptomatic patients remains controversial and is mainly based on individual 
risk stratification. Imaging is fundamental for the initial diagnostic work-up, follow-up, and selection of the optimal 
timing and type of intervention. The present review provides specific recommendations for utilization of multimodality 
imaging to optimize risk stratification and therapeutic decision-making processes in aortic stenosis.  (Circ Cardiovasc 
Imaging. 2016;9:e004352. DOI: 10.1161/CIRCIMAGING.115.004352.)
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Special Report
Calcific aortic stenosis (AS) is the most frequent valvular heart disease in developed countries.1 AS often has a long 
latency period before symptom onset; however, when symp-
toms develop and severe AS is present, the average survival is 
reduced to 2 to 3 years in the absence of treatment. Although 
surgical aortic valve replacement (AVR) or transcatheter aor-
tic valve implantation (TAVI) is the sole effective treatment for 
symptomatic severe AS, the postoperative outcome varies nota-
bly from one patient to another. Risk stratification in asymp-
tomatic patients and identification of markers of poor prognosis 
in symptomatic subjects have, thus, become key elements in the 
management of AS. Standard Doppler echocardiography is the 
cornerstone of the evaluation of AS, and in ≈65% to 70% of the 
patients, this imaging modality is sufficient to guide therapeutic 
management. However, in ≈25% to 30% of the patients, there 
are some uncertainties about AS severity at Doppler echocar-
diographic examination, and these patients may, thus, require 
multimodality imaging to confirm disease stage and guide 
therapeutic decision making.2–7 The present review provides 
specific recommendations based on the current literature on 
the utilization of multimodality imaging in AS.
New Classification of AS and 
Concept of Disease Stages
The 2014 American College of Cardiology (ACC)/American 
Heart Association (AHA) guidelines have introduced the con-
cept of disease staging for valvular heart disease, including AS 
(Figure 1),2 which has introduced additional degrees of complex-
ity in the classification of AS. The identification of disease stage 
is essentially based on the assessment of stenosis severity and 
left ventricular (LV) systolic function by Doppler echocardiog-
raphy and the patient’s symptomatic status. The symptomatic 
severe stage (D) includes patients who have developed symp-
toms as a result of severe AS. This stage is subdivided into 3 
stages: D1, D2, and D3 according to the flow-gradient classifica
tion of AS.3,4 All these entities are characterized by a small aortic 
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Figure 1. (Continued ).
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valve area (AVA; <1.0 cm2), thus suggesting severe AS, but they 
differ in terms of LV remodeling, systolic function, transvalvu-
lar flow, transvalvular pressure gradients, and outcomes. Patients 
with low LV ejection fraction (LVEF <50%) and LG (LG <40 
mm Hg) are referred as to classical low-flow (LF) LG AS and are 
classified as stage D2 in the ACC/AHA guidelines.2 This entity 
is characterized by depressed LV systolic function, LV eccentric 
remodeling, and poor outcomes with medical therapy but high 
surgical risk with surgical AVR.5,6 Patients with a small AVA and 
a preserved LVEF are then separated into 4 groups according to 
(1) flow, that is, LF defined by an indexed LV stroke volume <35 
mL/m2 versus normal flow (NF; ≥35 mL/m2) and (2) mean gra-
dient, that is, low (LG<40 mm Hg) versus high gradient (HG≥40 
mm Hg). An LF state is indeed commonly defined as an indexed 
LV stroke volume of <35 mL/m2, a cutoff associated with worse 
outcomes in AS.7,8 The 4 flow-gradient groups are, thus, (1) 
NF-HG, (2) LF-HG, (3) NF-LG, and (4) LF-LG.
The current guidelines make no distinction between the 
NF-HG and LF-HG AS, and these 2 entities are grouped together 
into the C1 or D1 stages depending on whether the patient is 
asymptomatic or symptomatic, respectively.2 In these patients, 
the stenosis is likely severe, and there is no need for additional 
diagnostic tests to corroborate severity. However, among patients 
with HG and preserved LVEF, those with LF generally have 
a worse prognosis both before and after AVR, compared with 
those with NF.4,7,9 The patients with preserved LVEF and LF-LG 
are referred as to paradoxical LF-LG AS, which is classified as 
stage D3 in the ACC/AHA guidelines, if the patient is symptom-
atic.2 In these patients, the decrease in stroke volume (<35 mL/
m2) and transvalvular flow is generally related to pronounced LV 
concentric remodeling (relative wall thickness, >0.5) with small 
LV cavity (end-diastolic volume index, <55 mL/m2), restric-
tive LV diastolic pattern, and reduced global longitudinal strain 
(global strain, <16%).3,8,10 However, the LF state may also occur 
because of concomitant mitral regurgitation, tricuspid regurgita-
tion, atrial fibrillation, constrictive pericarditis, or severe pulmo-
nary hypertension with right ventricular failure. Little is known 
about the natural history of paradoxical LF-LG AS.11–13
Figure 1 Continued. Algorithms proposed by the Heart Valve Clinic International Database (HAVEC) group for disease staging and man-
agement in patients with aortic valve stenosis. AS indicates aortic stenosis; AVA, aortic valve area; AVR, aortic valve replacement; CMR, 
cardiac magnetic resonance; DSE, dobutamine stress echocardiography; ESE, exercise stress echocardiography; EF, ejection fraction; 
HG, high gradient; LF, low flow; LG, low gradient; MPG, mean pressure gradient; MSCT, multislice computed tomography; NF, normal 
flow; and PET, positron emission tomography.
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Albeit there are some discrepancies, most of the previous 
studies report that among these 4 flow-gradient groups with 
small AVA and preserved LVEF, the one with paradoxical 
LF-LG AS has the worst prognosis and those with NF-LG AS 
has the best prognosis.4,7,14 Furthermore, AVR improves out-
comes in both patients with HG AS and those with paradoxical 
LF-LG AS. In patients with NF-LG AS, previous studies have 
yielded conflicting results on the effect of AVR on outcomes. 
This entity may, at least in part, be related to the inherent dis-
crepancy between the cut-point values of AVA (1.0 cm2) and 
mean gradient (40 mm Hg) proposed in the guidelines to identify 
severe AS.15 Indeed, an AVA of 1.0 cm2 corresponds to a mean 
gradient of 30 to 35 mm Hg rather than 40 mm Hg in a patient 
with NF rate, and as a consequence, several patients with mod-
erate-to-severe AS might have discordant AVA-gradient mea-
surements. Although the NF-LG entity is generally perceived as 
being a nonsevere form of AS, some recent studies using aortic 
valve calcium scoring by cardiac multislice computed tomog-
raphy (MSCT) suggest that up to 50% of these patients would 
have severe AS.16 Consistent with this finding, several studies 
report a potential survival benefit of AVR in these patients.17,18 
The guidelines provide no specific stage or recommendation of 
intervention for these patients with NF-LG. The Heart Valve 
Clinic International Database (HAVEC) group would suggest 
an integrated classification by creating new stages for these 
patients and those with LF-LG AS: patients with NF-LG, small 
AVA, and preserved LVEF would be classified as C4 stage if 
they are asymptomatic and D4 if they are symptomatic; and 
patients with LF-LG, small AVA, and preserved LVEF would 
be classified as C3 stage if they are asymptomatic (Figure 1).
Clinical Management of AS: New Challenges
In stages A and B, there is no indication of AVR (Figure 1A; 
Table 1). In stages C2 (severe AS with LV dysfunction) and 
D1 (symptomatic severe AS with HG), there is a class I indi-
cation for AVR.2 For these stages, transthoracic Doppler echo-
cardiography is generally sufficient, and there is no need for 
multimodality imaging. For patients in stage C1 (asymptom-
atic severe AS with HG), the challenge is to identify those 
who may need early prophylactic AVR (class IIa) versus 
those who can be safely managed with a wait-for-symptoms 
strategy. Multimodality imaging can play an important role 
to refine risk and optimize selection of the timing of AVR 
in these patients (Figure 2).19 The same approach should be 
applied to asymptomatic patients with paradoxical LF-LG AS 
(HAVEC C3 stage) although there is less evidence to support 
prophylactic AVR in these patients. When managed medi-
cally, a close follow-up is warranted. Aortic valve intervention 
might be considered (IIb) in high-risk patients identified by 
multimodality imaging (high calcium score, low global lon-
gitudinal strain, and extensive myocardial fibrosis by cardiac 
magnetic resonance [CMR]).
In symptomatic patients with LF-LG AS (stages D2 and 
D3), there is a class IIa recommendation of AVR.2 However, 
in the presence of LF-LG, the stenosis severity remains uncer-
tain and multimodality imaging is required to confirm steno-
sis severity and decide whether relief of valve obstruction is 
indicated. In patients with NF-LG AS (HAVEC C4 and D4 
stages), there is no specific recommendation in the guidelines 
Table 1. AHA/ACC and ESC Guidelines for Surgical AVR/TAVI 
in AS
ESC 2012 ACC/AHA 2014
Severe high-gradient AS (stages C1 and D1): preserved LVEF,  
MPG≥40 mm Hg, and AVA<1 cm2
  Symptoms related to severe AS I I
  Exercise-limiting symptoms during  
exercise testing
I I
  Asymptomatic with blood pressure drop 
during exercise testing or decreased exercise 
tolerance (AHA/ACC)
IIa IIa
  Asymptomatic severe AS undergoing other 
cardiac surgery
I I
  Asymptomatic patient with very severe  
AS (AHA/ACC, V
max





  Asymptomatic with calcified aortic valve+rapid 
stenosis progression (≥0.3 m/s per year; ESC) 
or rapid disease progression and low surgical 
risk (AHA/ACC)
IIa IIb
  Markedly elevated BNP values without other 
explanation
IIb …
  Increase of MPG with exercise ≥20 mm Hg IIb …
  Excessive LV hypertrophy in the absence of 
hypertension
IIb …
Asymptomatic severe high-gradient AS with reduced LVEF (stage C2):  
AVA <1 cm2 (normal or low flow)
  Asymptomatic AS with MPG>40 mm Hg  
or V
max
>4 m/s and LVEF<50%
I I
Classical low-flow, low-gradient symptomatic AS (stage D2): reduced LVEF, 
MPG<40 mm Hg, and AVA<1 cm2
  Symptomatic patients with severe LF/LG 
AS with reduced LVEF and evidence of flow 
reserve (AHA/ACC if true severe AS)
IIa IIa
  Symptomatic patients with severe LF/LG AS and 
LV dysfunction without flow reserve during DSE
IIb …
 Moderate symptomatic/asymptomatic AS (stage B): MPG<40 mm Hg  
and AVA≥1 cm2
  Moderate AS (AVA between 1.0 and 1.5 cm2 or 
indexed AVA between 0.6 cm2/m2 and  
0.9 cm2/m2 or MPG between 25 and 40 mm Hg 
according to ESC or V
max
 between 3 and 3.9 
m/s according to AHA/ACC undergoing other 
cardiac surgery
IIa IIa
  Symptomatic moderate AS with reduced LVEF … …
Normal-flow, low-gradient symptomatic AS (HAVEC stage D4): preserved LVEF, 
MPG<40 mm Hg, AVA<1 cm2, and SVi<35 mL/m2
  Symptomatic normal-flow, low-gradient severe AS … …
Paradoxical low-flow, low-gradient symptomatic AS (stage D3): preserved 
LVEF, MPG<40 mm Hg, AVA<1 cm2, indexed AVA<0.6 cm2/m2, and  
SVi<35 mL/m2
  Symptomatic patients with LF/LG severe AS and 
preserved LVEF only after careful confirmation 
of AS severity
IIa IIa
AHA/ACC indicates American Heart Association/American College of Cardiology; 
AS, aortic stenosis; AVA, aortic valve area; AVR, aortic valve implantation; BNP, 
brain natriuretic peptide; DSE, dobutamine stress echocardiography; ESC, 
European Society of Cardiology; LF, low flow; LG, low gradient; LVEF, left ventricular 
ejection fraction; MPG, mean pressure gradient; SVi, stroke volume index; TAVI, 
transcatheter aortic valve implantation; and V
max
, aortic jet velocity.
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and multimodality imaging may be helpful for individual risk 
stratification, adjust the frequency of the echo/clinical follow-
up, and eventually recommend intervention. In patients with 
NF-LG AS, surgical AVR could be considered if multimo-
dality imaging confirms that the stenosis is severe and if the 
patient is symptomatic (HAVEC D4 stage; Figure 1C). If the 
patient is asymptomatic (HAVEC C4 stage), a conservative 
approach should probably be recommended (Figure 1B).
Multimodality Imaging 
Assessment of AS Severity
Transthoracic Doppler Echocardiography
A comprehensive echocardiography report should contain 
information on aortic valve morphology (bicuspid versus tri-
cuspid) and mobility, cause and severity of AS (AVA, mean 
gradient, and peak aortic jet velocity), and its consequences 
on LV function (stroke volume, LVEF, and diastolic function), 
left atrial pressure, and pulmonary arterial pressure (Data 
Supplement). The continuity equation is used to calculate the 
AVA. The LV outflow tract (LVOT) diameter should be sys-
tematically reported to allow accurate monitoring of stenosis 
progression during follow-up. The LVOT diameter should be 
measured at the base of the aortic valve cusps or 1 to 5 mm 
below the aortic annulus using the zoomed view of the LVOT 
providing the largest diameter (distal LVOT diameter, relative 
to the direction of blood flow; Data Supplement). Recent stud-
ies suggest that the measurement of LVOT diameter >5 to 10 
mm below the aortic annulus (proximal LVOT diameter, rela-
tive to the direction of flow) is less accurate and reproducible 
to estimate stroke volume and AVA.20
Multiple echocardiographic windows and a good Doppler 
alignment to the flow direction are used to detect the high-
est aortic jet velocity. Accurate interpretation of the echocar-
diographic data requires reporting the level of systolic blood 
pressure (optimal level, <140 mm Hg) and the diameter of the 
ascending aorta. Hypertension may contribute to increase LV 
afterload and decrease LV outflow, and it may, thus, interfere 
with the Doppler echocardiographic assessment of stenosis 
severity.21 The calculation of the valvuloarterial impedance 
(Z
va
) can easily be performed as part of a routine echocardio-
graphic examination and provides an estimate of the global 
(valvular+vascular) hemodynamic load.22
Doppler echocardiography may overestimate the trans-
valvular pressure gradient compared with left heart catheter-
ization in the presence of a small ascending aorta (diameter 
A
B
Figure 2. Risk factors predicting poor spontaneous 
outcome in patients with asymptomatic severe aor-
tic stenosis (AS; stage C1; A) or with classical low-
flow, low-gradient AS and reduced left ventricular 
ejection fraction (stage D3; B). AV indicates aortic 
valve; AF, atrial fibrillation; BNP, brain natriuretic 
peptide; CAD, coronary artery disease; CMR, car-
diac magnetic resonance; ΔMG, change in mean 
pressure gradient; DSE, dobutamine stress echo-
cardiography; ESE, exercise stress echocardiog-
raphy; GLS, global longitudinal strain; LAi, indexed 
left atrium area; LV, left ventricle; LVEF, LV ejection 
fraction; MPG, mean pressure gradient; MSCT, 
multislice computed tomography; PW-TDI, pulsed 
wave tissue Doppler at the mitral annulus; SPAP, 
systolic pulmonary artery pressure; and SV, stroke 
volume. Reprinted from Magne et al19 with permis-
sion of the publisher. Copyright ©2015, Elsevier.
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of ascending aorta, <30 mm) because of significant pressure 
recovery downstream of the valve.22,23 Finally, the assessment 
of indexed LV mass and relative wall thickness is used to 
define the pattern of LV remodeling. Severe AS is expected 
to be associated with an abnormal LV remodeling pattern. If 
the LV mass and geometry are normal, it is unlikely that the 
patient has severe AS.
Transesophageal Echocardiography
Transesophageal echocardiography has the advantage of a 
higher spatial resolution and is useful to grade AS severity in 
patients with poor transthoracic acoustic windows in whom 
the measurement of the LVOT diameter and anatomic or geo-
metric AVA by planimetry is not feasible or inaccurate. The 
measurement of effective AVA is also possible using the con-
tinuity equation provided that a good Doppler alignment to 
the flow direction is achieved from the transgastric view. It is 
important to underline that anatomic and effective AVAs are 
not equivalent from a physiological standpoint.24 Indeed, the 
effective AVA is often smaller than the anatomic AVA because 
of the flow contraction that occurs between the anatomic ste-
nosis and the vena contracta of the transvalvular flow jet. So, 
when the anatomic AVA is <1 cm2 and the valve is severely 
calcified, the stenosis is often considered severe. In the case 
of uncertainties about AS severity using the planimetry or sig-
nificant discordance with the effective AVA, other approaches 
should be used. Transesophageal echocardiography is also 
particularly useful before TAVI to evaluate the aortic annulus 
and the ascending aorta.
Three-Dimensional Echocardiography
Three-dimensional (3D) echocardiography can help in assess-
ing AS severity. When compared with the transesophageal 
approach, 3D transthoracic echocardiography has lower spa-
tial resolution and its quality depends on the acoustic win-
dows. However, 3D transesophageal echocardiography has a 
satisfactory spatial resolution and may be useful to comple-
ment a nonconclusive 2D echo study. The AS severity can be 
estimated as follows: (1) guided 2D planimetry of the leaflet 
tips using a 3D data set that is cropped to obtain anatomic 
orifice area; (2) optimized computation of the effective ori-
fice area using the continuity equation and the planimetry 
of the cross-sectional area of the LVOT without any geo-
metric assumption from a 3D data set; (3) estimation of the 
3D-derived stroke volume in the continuity equation using 
3D LV end-diastolic and end-systolic volumes (providing that 
there is no significant mitral regurgitation, preferentially from 
a 3D transthoracic data set); and (4) 3D stroke volume mea-
sured by real-time volume color Doppler across the LVOT. 
Estimation of the LVOT area by 2D echocardiography is based 
on the measurement of the sagittal diameter in the parasternal 
long-axis view, and it assumes that the LVOT has a circular 
cross-section, which is often not the case (Data Supplement). 
When the shape of the LVOT is elliptical, the utilization of the 
sagittal diameter, which is generally smaller than the coronal 
diameter, may result in underestimation of LVOT area and, 
thus, of stroke volume and effective AVA. 3D transesophageal 
echocardiography proved also superior to 2D echocardiogra-
phy to measure aortic annulus size (minimum and maximum 
diameters and annulus perimeter) and shape before TAVI.25 
Results obtained by 3D transesophageal echocardiography 
are similar to MSCT or CMR-derived diameters and can be 
used for selection of transcatheter valve size to reduce the risk 
of paravalvular regurgitation.25 3D transesophageal echocar-
diography could be particularly useful to size the prosthesis 
dimension before TAVI in patients with severe chronic kidney 
disease to avoid the use of contrast agents.
Exercise Testing and Stress Echocardiography
Stress echocardiography is useful to confirm stenosis severity 
in patients with LF-LG AS and to identify patients at high risk 
of cardiovascular events in the case of asymptomatic severe 
AS (Table 2). Protocols, guide for referral, procedure, and 
reporting for valve stress echocardiography have been recently 
discussed.26 In asymptomatic severe AS (C1 stage), exercise is 
the optimal stressor and is a class IIa indication in the ACC/
AHA guidelines, whereas it is strongly advocated in the Euro-
pean Society of Cardiology recommendations.2,27 Exercise 
testing or exercise stress echocardiography using a modified 
Bruce protocol is useful to unmask symptoms in patients with 
severe AS who claim to be asymptomatic (Table 2). Indeed, 
about one third of patients with apparently no symptoms on 
medical questionnaire have exercise-limiting symptoms on 
exercise testing, and these patients have worse outcome.28–30 
Beyond symptom development, a drop in systolic blood pres-
sure by >20 mm Hg is also predictive of outcome.28 Although 
a negative exercise test is reassuring in younger patients, the 
predictive value of the test is improved when combined with 
echocardiographic assessment of LV function,31 transvalvular 
pressure gradients,28,32 and pulmonary arterial pressure.33 An 
exercise increase in mean gradient ≥18 to 20 mm Hg,28,32 the 
absence of contractile reserve (no or <5% exercise increase in 
LVEF),34 or the presence of exercise pulmonary hypertension 
(>60 mm Hg)33 are all strong predictors of cardiac events.
Low-dose (≤20 μg/kg per minute) dobutamine echocar-
diography is recommended (class IIa) in patients with sus-
pected classical LF-LG AS and reduced LVEF2 and could be 
useful in patients with paradoxical LF-LG AS in the absence 
of potential contraindications (Table 2).35 According to ACC/
AHA guidelines, a true severe AS is identified when the mean 
gradient is ≥40 mm Hg and AVA is ≤1.0 cm2 at any dobutamine 
stage.2 This criterion is highly sensitive but lacks specificity, 
and it can only be achieved in patients who have significant 
LV flow reserve (ie, increase is stroke volume >20%). In 
patients with no flow reserve, the stenosis severity generally 
remains undermined with dobutamine stress echocardiogra-
phy because the increase in flow is not sufficient to induce 
any change in AVA or gradient. Furthermore, in the frequent 
situation of patients with some degree of flow reserve but with 
peak stress flow rate remaining below normal at peak dose of 
dobutamine, the AVA (<1.0 cm2)–gradient (<40 mm Hg) dis-
cordance that exists at rest often persists during the test. When 
the effective AVA increases (European Society of Cardiology 
definition: change, >0.3 cm2; effective AVA, >1.2 cm2; AHA/
ACC definition AVA, >1 cm2) but the mean gradient remains 
<40 mm Hg, pseudosevere AS (LV systolic dysfunction not 
related to AS) is considered to be present.2,27 When the stroke 
volume increase is <20% and no significant changes in mean 
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gradient and AVA are observed, AS severity remains inde-
terminate. In these patients, we recommend to calculate the 
projected AVA at NF rate (250 mL/s) to reconcile this discor-
dance.36 A projected AVA of ≤1.0 cm2 or indexed projected 
AVA of ≤0.55 cm2/m2 confirms the presence of true severe AS 
and predicts the risk of cardiac events.36 However, it should be 
kept in mind that data on the cutoff values of stroke volume 
increase during the dobutamine test come from small stud-
ies on a limited number of patients and should be interpreted 
cautiously. In practice, a patient who does not have >20% 
increase in stroke volume but has a significant increase in gra-
dient (mean pressure gradient>40 mm Hg), nonparalleled by 
an increase in AVA (AVA<1.0 cm2), should be considered as 
having true severe AS (stage D2).
Cardiac MSCT
Cardiac MSCT allows visualization of the aortic valve and 
cardiac chambers throughout the cardiac cycle and provides 
information about the aortic valve morphology (ie, bicuspid 
versus tricuspid valve), LV dimensions, coronary artery anat-
omy, coronary ostia localization, leaflet length, aortic annulus 
size, and aortic root morphology and dimensions. MSCT has 
a high spatial resolution and is particularly useful in patients 
with poor transthoracic acoustic windows or contraindica-
tion to transesophageal echocardiography. Using 3-multipla-
nar reformations, from left sagittal oblique and left coronal 
oblique views, a cross-sectional view of the aortic valve can 
be generated for accurate measurement of anatomic AVA.37 
MSCT allows accurate measurement of aortic annulus diam-
eters (sagittal+coronal+mean values), area, and perimeter, 
which are key parameters for the selection of the prosthe-
sis size before TAVI.38 Protruding annular calcium (into the 
lumen) with >4 mm in size, severe aortic annular calcification 
(high calcium score), and undersizing of the transcatheter 
valve relative to the annulus size are the main predictors of 
postprocedural paravalvular regurgitation.39
Typically, the annulus size is larger with MSCT, 3D echo-
cardiography, or CMR than when measured with either 2D 
Table 2. Recommendations of the Heart Valve Clinic International Database (HAVEC) Group for the Indication of Multimodality 
Imaging in the Clinical Management of AS
Disease Stage Definition of Disease Stage Echo DSE ESE CMR MSCT PET
A At risk of developing AS I III III III III III
B Progressive mild-to-moderate 
AS
I … … … … …
C1 Asymptomatic NF/LF high- 
gradient severe AS
I III I (to assess 
symptoms and valve 
hemodynamics)
IIb (to assess 
myocardial fibrosis)
IIa (for its prognostic 
implications)
IIb (for its 
prognostic 
implications)
C2 Asymptomatic NF/LF high- 
gradient severe AS with 
LVEF<50%
I … … … … …
C3* Asymptomatic LF-LG AS with 
preserved LVEF
I IIb (to distinguish 
between severe and 
pseuodosevere AS)
IIa (to assess 
symptoms and valve 
hemodynamics 
and to distinguish 
between severe and 
pseudosevere AS)
IIb (to assess 
myocardial fibrosis)
IIa (for its prognostic 
implications and to 
distinguish severe from 
pseudosevere AS)
…
C4* Asymptomatic NF/LG AS with 
preserved LVEF
I IIb (to distinguish 
between severe and 
pseuodosevere AS)
IIa (to assess 
symptoms and valve 
hemodynamics 
and to distinguish 
between severe and 
pseudosevere AS)
IIb (to assess 
myocardial fibrosis)
IIa (for its prognostic 
implications and to help 
distinguish severe AS 
from moderate AS)
…
D1 Symptomatic NF/LF high- 
gradient severe AS
I … III … … …
D2 Symptomatic LF-LG AS with 
reduced LVEF
I I (to distinguish 
between severe 
and pseuodosevere 
AS and evaluate 
contractile reserve)
III IIa (to assess 
myocardial fibrosis)
IIa (to help distinction 
between severe and 
pseudosevere AS in 
patients with no flow 
reserve)
…
D3 Symptomatic LF-LG AS with 
preserved LVEF
I IIa (to help distinction 
between severe and 
pseudosevere AS)
III IIa (to assess 
myocardial fibrosis)
I (to help distinction 
between severe and 
pseudosevere AS)
…
D4* Symptomatic NF/LG severe AS 
with preserved LVEF
I IIa (to help distinction 
between severe and 
pseudosevere AS)
III IIb (to assess 
myocardial fibrosis)
I (to help distinction 
between severe and 
pseudosevere AS)
…
—: not relevant. AS indicates aortic stenosis; CMR, cardiac magnetic resonance; DSE, dobutamine stress echocardiography; echo, echocardiography; ESE, exercise 
stress echocardiography; I, indicated; IIa, should be considered; IIb, may be considered; III, not recommended; LF, low flow; LG, low gradient; LVEF, left ventricular 
ejection fraction; MSCT, multislice computed tomography; NF, normal flow; and PET, positron emission tomography.
*Additional HAVEC disease stages.
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transthoracic or transesophageal echocardiography (absolute 
difference, ≤1.52±1.1 mm).37,38
Aortic valve calcium scoring (Data Supplement) can also 
help discriminate severe from nonsevere AS in patients with 
discordant echocardiographic findings and particularly in 
patients with LF-LG AS and those with NF-LG AS who are 
characterized by a small AVA consistent with severe AS but 
a LG consistent with nonsevere AS.16 Different cutoff values 
of aortic valve calcium score should be used in men (≥2000 
AU or ≥480 AU/cm2) versus women (≥1200 AU or ≥290 AU/
cm2) to identify severe AS.16,40 A potential explanation for 
this intriguing finding is that women have relatively more 
valvular fibrosis than men. Fibrosis may also contribute to 
valvular stenosis, but as opposed to calcification, it is not 
detected by MSCT. Aortic valve calcium scoring by MSCT is 
particularly helpful when dobutamine stress echocardiogra-
phy is not feasible or not conclusive, which is often the case 
in patients with classical LF-LG AS (D2 stage) and no flow 
reserve, in patients with paradoxical LF-LG (D3 stage), and 
in patients with NF-LG AS (HAVEC D4 stage; Figure 1). 
This imaging technique might also be useful to corroborate 
stenosis severity in asymptomatic patients with preserved 
LVEF, LG, and LF or NF (HAVEC C3 or C4 stages). It may 
be used in such cases depending on the local expertise and 
availability.
The aortic valve calcium load assessed by MSCT is also 
a powerful predictor of rapid stenosis progression and of car-
diac events in patients with AS; it could be used to enhance 
individualized risk stratification in C1 stage AS.41
Cardiac Magnetic Resonance
CMR has emerged as an alternative noninvasive modal-
ity without ionizing radiation and is indicated as a comple-
mentary imaging when transthoracic or transesophageal 
echocardiography is nondiagnostic (Table 2). CMR provides 
images of valve anatomy and motion and allows quantitative 
evaluation of AS and LV function. CMR planimetry for the 
assessment of anatomic AVA is possible but less than optimal 
in patients with calcific AS, especially when a nonplanar ori-
fice exists.42 Other standard measures of stenosis severity can 
be obtained with CMR: peak anterograde velocity, pressure 
gradient, and effective AVA. Velocities and gradients are often 
underestimated with CMR when compared with Doppler 
echocardiography.43 CMR also has the ability to characterize 
the pattern and volume of myocardial fibrosis (focal versus dif-
fuse; subendocardial versus midwall)44,45 (Data Supplement). 
CMR late-gadolinium enhancement provides an estimation 
of the degree of focal fibrosis, which corresponds to replace-
ment fibrosis most often related to ischemic heart disease or 
severe pressure-overload cardiomyopathies, such as in AS. In 
AS, myocardial fibrosis is one of the major processes driv-
ing the decompensation of the LV and the progression toward 
symptoms, heart failure, and adverse events. T1 mapping of 
extracellular volume provides an estimate of diffuse fibrosis, 
which consists, in large part, of reactive interstitial fibrosis and 
is more specific to pressure-overload cardiomyopathies. Some 
studies have shown that the presence of myocardial fibrosis in 
the midwall layer is more specific to AS rather than to isch-
emic heart disease and is a more powerful predictor of cardiac 
events.44
Positron Emission Tomography/CT
Positron emission tomography (PET)/CT is a feasible and 
reproducible method that combines the anatomic informa-
tion from CT with the functional information derived from 
PET. 18F-sodium fluoride (18F-NaF) is a PET tracer that 
exchanges with hydroxyl groups on hydroxyapatite crys-
tals, a key structural component of both bone and vascular 
calcification. A recent study has shown that 18F-NaF, with 
high specificity and sensitivity, binds to calcium deposits 
in human atherosclerothic vascular tissue and is a useful 
tool to assess areas of vascular microcalcification noninva-
sively.46 Increased 18F-NaF uptake has been also described 
in AS, where it is believed to identify areas of increased 
calcification activity.47 The magnitude of increased 18F-NaF 
activity correlates well with disease severity.48 In a recent 
study, PET/CT had the ability to predict disease progression 
(both as assessed by echocardiography and MSCT) and the 
development of adverse clinical events.49 18F-fluorodeoxy-
glucose is another PET tracer whose uptake has been linked 
to macrophage burden in the carotid arteries and which can 
be used to measure metabolic activity in the aortic valve as 
a surrogate for inflammation.48 The uptake of 18F-fluorode-
oxyglucose, which reflects valvular inflammation, is higher 
in patients with mild or moderate AS compared with con-
trols but decreased in the severe AS stage. In contrast, the 
uptake in 18F-NaF increases progressively with each stage of 
AS severity and is maximal in severe AS (Data Supplement). 
Of note, the increase in 18F-NaF is also higher in AS than in 
aortic atheroma, whereas the opposite situation is seen for 
18F-fluorodeoxyglucose, indicating that inflammation seems 
to have a lesser role in advanced AS and vice versa. Active 
mineralization may be predominant in the pathogenesis of 
Table 3. Recommendations of the Heart Valve Clinic 
International Database (HAVEC) Group for the Timing of Follow-Up 
of Multimodality Imaging in the Clinical Management of AS
Disease 
Stage Echo DSE ESE CMR MSCT PET
A 5 y … … … … …
B 2–3 y … … … … …
C1 6 mo … 1 y 2 y … …
C2 3 mo … … … … …
C3* 6 mo … 1 y 2 y … …
C4* 6 mo … 1 yr 2 yr … …
D1 3 mo … … … … …
D2 3 mo … … … … …
D3 3 mo … … … … …
D4* 6 mo … … … … …
ESE may be repeated each year in asymptomatic patients with severe AS to 
confirm the absence of symptoms and search for markers of poor prognosis, 
such as a significant increase in mean pressure gradient. CMR may be 
used each 2 years in asymptomatic patients to test for the development of 
myocardial fibrosis, an important prognostic factor in severe AS. AS indicates 
aortic stenosis; CMR, cardiac magnetic resonance; DSE, dobutamine stress 
echocardiography; ESE, exercise stress echocardiography; MSCT, multislice 
computed tomography; and PET, positron emission tomography.
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the disease. PET/CT, 18F-NaF, as a marker of calcification 
activity, is a good predictor of aortic valve calcium score 
progression by MSCT at 1 year.47
Role of Multimodality Imaging for Patient Follow-Up
AS is characterized by a long asymptomatic phase, lasting 
several decades, during which outflow obstruction develops 
progressively. Generally, prognosis is considered fair in mild-
to-moderate stages (stage A and B), and risks of symptoms 
and death are expected to correlate with the hemodynamic 
degree of AS severity.50 However, because of wide variability 
in clinical (risk of sudden death varying from <1% to 5%)30,33,51 
and hemodynamic progression (event-free survival at 5 years 
varying from 30% to 80% in severe AS),50,51 appropriate moni-
toring of disease status and individual risk stratification is war-
ranted. Follow-up examinations are suggested to be obtained 
in a Heart Valve Center of Excellence,2,52 whenever possible 
(Table 3). Monitoring should look for any change in symp-
tomatic status, in exercise tolerance ideally with an exercise 
test, in LV function, or in disease severity.
Specific Clinical Scenarios
Asymptomatic Severe AS—Stage C1
In this category of patients, a stepwise approach is advo-
cated: (1) identification of patients with very severe stenosis 
(peak velocity, ≥5.0 m/s) and (2) determination of whether 
the patient is truly asymptomatic and has a normal blood 
pressure response during exercise (Figure 3A). As a sec-
ond step, further imaging-based risk assessment should be 
considered and include the assessment of (1) risk factors 
of rapid stenosis progression: severe aortic valve calcifica-
tion on echo or MSCT, marked increase in mean pressure 
gradient (>18–20 mm Hg) during exercise echo; and (2) 
markers of more advanced LV dysfunction: LF (indexed 
LV stroke volume<35 mL/m2),53 high Z
va
 (>4.5–5 mm Hg/
mL/m2),54 decreased longitudinal LV function (global 
strain<16%),54 enlarged left atrium (indexed left atrial area, 
≥12.2 cm2/m2),54 and high brain natriuretic peptide level 
(ratio-measured brain natriuretic peptide/normal reference 
brain natriuretic peptide for age and sex, >2).55 CMR is not 
yet routinely indicated for risk stratification. However, this 
imaging modality may be useful to detect and quantitate 
myocardial fibrosis. When a watchful strategy is selected 
for a patient in C1 stage, the presence of any of the above-
mentioned parameters underlines the need for closer follow-
up (every 3 months).
Classical LF-LG AS—Stage D2
Because the resting echocardiographic examination in these 
patients is unable to ascertain the stenosis severity, a multi-
modality/imaging approach is mandatory (Figure 3B). Dobu-
tamine stress echocardiography is the first-line recommended 
Figure 3. (Continued ).
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test to confirm stenosis severity and assess the presence of 
flow reserve. The absence of flow reserve should not preclude 
surgical AVR although TAVI may be a valuable alternative in 
such patients. In patients with indeterminate AS severity at 
dobutamine stress echocardiography (even after calculation 
of projected AVA), CT calcium scoring by MSCT can help 
Figure 3 Continued. Algorithm proposed for individual risk stratification in severe asymptomatic aortic stenosis (AS; A), in low-flow (LF), low-
gradient (LG) AS and reduced left ventricular ejection fraction (EF; B), and in LF, LG AS and preserved left ventricular EF (C). AVC indicates aortic 
valve calcification; AVR, aortic valve replacement; BNP, brain natriuretic peptide; BSA, body surface area; CMR, cardiac magnetic reso-
nance; DSE, dobutamine stress echocardiography; ESE, exercise stress echocardiography; GLS, global longitudinal strain; LF, low flow; LG, 
low gradient; MPG, mean pressure gradient; MSCT, multislice computed tomography; NF, normal flow; PET, positron emission tomography; 
PHT, pulmonary hypertension; SBP, systolic blood pressure; SV, stroke volume; and TAVI, transcatheter aortic valve implantation.
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differentiate severe from moderate stenosis.16 CMR identifica-
tion of extensive necrosis/fibrosis may also orientate toward 
TAVI because of its lower risk of cardiodepressive effects 
when compared with surgical AVR. Of note, European Soci-
ety of Cardiology–European Association for Cardio-Thoracic 
Surgery guidelines consider an LVEF of <20% as a relative 
contraindication for TAVI.27
Symptomatic Paradoxical LF-LG AS With 
Preserved LVEF—Stage D3
As for classical LF-LG AS—stage D2, confirmation of AS 
severity in symptomatic patients with paradoxical LF-LG 
AS requires multimodality/imaging approaches (Data Sup-
plement). The recommended stepwise algorithm is depicted 
in Figure 3C: (1) rule out measurement errors; (2) calculate 
AVA indexed to body surface area to rule out the situation 
of small AVA in a small patient, which would correspond 
to a moderate AS; (3) identify the causal factors and fea-
tures of LF-LG AS (pronounced concentric LV remodeling, 
small LV cavity, reduced longitudinal function, moderate-
to-severe LV diastolic dysfunction, mitral stenosis, mitral 
regurgitation, tricuspid regurgitation, and atrial fibrillation); 
(4) redo the echo measurements after blood pressure control 
and confirm the LF state by 2D/3D echo volumetric meth-
ods or CMR; and (4) differentiate true versus pseudosevere 
stenosis with the use of stress echocardiography if feasible 
or MSCT (high AVC).16,35 Some recent studies suggest that 
TAVI may be preferable to surgical AVR in patients with par-
adoxical LF-LG AS because these patients are at higher risk 
of operative mortality and prosthesis–patient mismatch with 
surgical AVR.7,56 In these patients, it may also be useful to 
assess the extent of myocardial fibrosis by CMR to enhance 
risk stratification.10,44
Symptomatic NF-LG AS With Preserved  
LVEF—Stage D4
Patients with NF-LG AS and preserved LVEF (HAVEC stage 
D4) are generally believed to be at less advanced stage of 
the disease than patients in LF-LG AS (stages D2 and D3). 
However, recent studies suggest that a substantial propor-
tion may nonetheless have severe AS despite the LG and NF 
pattern. Hence, in symptomatic patients with NF-LG AS, it 
is important to corroborate stenosis severity preferably with 
the use of MSCT aortic valve calcium scoring. The same cut 
points as those used for LF-LG AS can be applied to these 
(8)  PET-CT with 18F-NaF may be useful in asymptomatic patients with 
severe AS (C1 stage) to identify the patients who are at higher risk of 
rapid stenosis progression and who may, thus, benefit from an earlier 
intervention. However, further studies are needed to demonstrate the 
incremental value of PET-CT 18F-NaF over the simple aortic valve calcium 
scoring by MSCT to predict stenosis progression rate and cardiac events.
AS indicates aortic stenosis; AVA, aortic valve area; AVR, aortic valve 
implantation; CMR, cardiac magnetic resonance; CT, computed tomography; 
LF, low flow; LG, low gradient; LVEF, left ventricular ejection fraction; LVOT, left 
ventricular outflow tract; MSCT, multislice computed tomography; NF, normal 
flow; PET, positron emission tomography; TAVI, transcatheter aortic valve 
implantation; and TEE, transesophageal echocardiography.
Table 4. ContinuedTable 4. Key Points From the Heart Valve Clinic International 
Database (HAVEC) Group on the Imaging Assessment of 
Patients With Severe AS
(1)  Transthoracic Doppler echocardiography is generally sufficient to make 
an accurate diagnosis of severe AS and guide decision making in most 
patients. However, a multimodality imaging approach is necessary in 
symptomatic patients with LF-LG AS (D2 and D3 stages) and potentially 
useful in patients with asymptomatic severe AS (C1 stage), asymptomatic 
LF/NF-LG AS, and preserved LVEF (HAVEC C3 and C4 stages), or 
symptomatic NF-LG AS (HAVEC D4 stage).
(2)  Transthoracic Doppler echocardiography is the first imaging approach 
to evaluate AS severity and is sufficient for an accurate diagnosis and 
treatment decision in stages A, B, and C2. In practice, we recommend to 
measure the LVOT diameter at the base of the aortic valve cusps or 1 to 5 
mm below. The LVOT diameter and the highest aortic peak velocity using 
multiple windows should be reported. When both blood pressure and Z
va
 
are elevated (>4.5–5 mm Hg/mL per m2), antihypertensive therapy should 
be initiated/optimized and the echocardiographic examination should 
be repeated after normalization of blood pressures. The pattern of LV 
remodeling should be described.
(3)  TEE is recommended in the case of nondiagnostic TTE because of poor 
acoustic window or inconclusive TTE or to evaluate the aortic annulus/
ascending aorta before TAVI.
(4)  3D echocardiography should be considered in patients who have 
paradoxical LF-LG AS at 2D echocardiography (stages C3 HAVEC and D3) 
to corroborate the measurements of stroke volume and effective AVA. This 
imaging modality may also be used in place of or in complement of MSCT 
or CMR to measure the aortic annulus area/perimeter and select the most 
appropriate valve size in patients undergoing TAVI.
(5)  Exercise testing is the first test to identify truly asymptomatic patients. 
Exercise stress echocardiography provides incremental information for risk 
stratification in C1 stage patients and could be useful (1) to determine the 
relevance and optimal timing of early elective AVR and (2) to assess the 
potential need for AVR before high-risk noncardiac surgery. This imaging 
technique may also be useful in patients with C3 and C4 HAVEC stages 
to assess stenosis severity and enhance risk stratification. Dobutamine 
stress echocardiography should be considered in stages D2 and HAVEC 
C3 to differentiate true severe from pseudosevere AS and to evaluate the 
operative risk and inform the selection process between surgical AVR and 
TAVI in stage D2. When ambiguous dobutamine stress results are obtained 
(insufficient increase in stroke volume), we recommend computing the 
projected AVA at normal flow rate.
(6)  Aortic valve calcium scoring by MSCT should be considered in (1) patients 
with a small AVA and LG AS (D2, D3, D4, C3, and C4 stages) to corroborate 
stenosis severity when dobutamine stress echo is not feasible or not 
conclusive and (2) patients with asymptomatic severe AS to identify those 
at higher risk for rapid disease progression who may benefit from earlier 
intervention (C1 stage). MSCT with contrast injection should be performed 
in patients with planned TAVI procedure to measure aortic annulus/root 
anatomy/dimensions.
(7)  Measurement of AVA by CMR has little role in patients with LF-LG 
AS (D2, D3, and C3 stages) to corroborate stenosis severity unless 
it is associated with the dobutamine stress test, which increases 
the complexity and duration of the procedure. The localization and 
quantification of myocardial fibrosis by CMR may potentially be useful to 
optimize risk stratification and timing of AVR in asymptomatic patients 
with severe AS (C1 and HAVEC C3 and C4 stages). Indeed, patients 
with more advanced fibrosis might be considered for early intervention 
to prevent the development of potentially irreversible myocardial 
dysfunction and symptoms and to enhance risk stratification and guide 
the selection of the type of intervention in patients with LF-LG AS (D2 
and D3 stages). Patients with extensive myocardial fibrosis are at higher 
risk of operative mortality and lack of functional improvement after 
surgical AVR.
(Continued )
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patients. If MSCT supports the presence of severe stenosis 
in such patients, AVR may be considered (HAVEC group 
recommendation).
Future Research Directions
Although imaging plays a major role in the management of 
patients with AS, there is a need for large-scale registries and 
studies to strengthen its clinical value. This is one of the major 
goals of the HAVEC group. Imaging is still poorly implemented 
in the individual risk stratification of patients with AS. Although 
more recent scoring systems have included some imaging data, 
effort should be made to identify new imaging parameters that 
could be added to modern risk calculators. The choice between 
surgical AVR versus TAVI is currently mainly based on clinical 
risk assessment and evaluation of the heart team. The additional 
value of imaging in the decision-making process is clear but 
still limited to the sizing of the aortic annulus and root and the 
assessment of the peripheral arterial tree. Whether the CMR 
detection of myocardial fibrosis should be systematically added 
to the imaging evaluation work-up is unknown. Reversibility 
of myocardial fibrosis and associated dysfunction after surgi-
cal AVR or TAVI most likely depends on the type (interstitial 
versus replacement) and extent (mild versus severe) of fibro-
sis. Data on the role of CMR for monitoring the progression of 
fibrosis and the prognostic effect of diffuse fibrosis by T1 map-
ping are also lacking. Progression of AS is substantially unpre-
dictable and cannot be mitigated by current medical treatments. 
However, new generations of drugs are under development, 
which may slow down or stop the fibrocalcific process. PET/
CT, by evaluating local inflammatory processes taking place in 
the valve leaflets, might be used to evaluate the effects of these 
agents on progression of AS.
Conclusions
Grading AS severity and ensuing therapeutic decision remains 
challenging especially in the context of LF state. Multimodal-
ity/multiparametric imaging is important for disease staging, 
risk stratification, and therapeutic decision making (Table 4). 
Imaging parameters should be interpreted in conjunction with 
the clinical findings, the circulating biomarkers, and the symp-
tomatic status. Repeated evaluation is warranted over time for 
adequate monitoring to assess the rate of progression of ste-
nosis severity and any change in LV function. New imaging 
targeting inflammation, calcifications, or myocardial fibrosis 
may pave new ways for tailored medical strategy.
Acknowledgments
The HAVEC group is made of volunteers who have put together a 




 1. Osnabrugge RL, Mylotte D, Head SJ, Van Mieghem NM, Nkomo VT, 
LeReun CM, Bogers AJ, Piazza N, Kappetein AP. Aortic stenosis in the 
elderly: disease prevalence and number of candidates for transcatheter 
aortic valve replacement: a meta-analysis and modeling study. J Am Coll 
Cardiol. 2013;62:1002–1012. doi: 10.1016/j.jacc.2013.05.015.
 2. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton 
RA, O’Gara PT, Ruiz CE, Skubas NJ, Sorajja P, Sundt TM 3rd, Thomas 
JD; American College of Cardiology/American Heart Association Task 
Force on Practice Guidelines. 2014 AHA/ACC guideline for the manage-
ment of patients with valvular heart disease: executive summary: a report 
of the American College of Cardiology/American Heart Association Task 
Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2438–2488. 
doi: 10.1016/j.jacc.2014.02.537.
 3. Dumesnil JG, Pibarot P, Carabello B. Paradoxical low flow and/or low 
gradient severe aortic stenosis despite preserved left ventricular ejec-
tion fraction: implications for diagnosis and treatment. Eur Heart J. 
2010;31:281–289. doi: 10.1093/eurheartj/ehp361.
 4. Lancellotti P, Magne J, Donal E, Davin L, O’Connor K, Rosca M, 
Szymanski C, Cosyns B, Piérard LA. Clinical outcome in asymptomatic 
severe aortic stenosis: insights from the new proposed aortic stenosis grad-
ing classification. J Am Coll Cardiol. 2012;59:235–243. doi: 10.1016/j.
jacc.2011.08.072.
 5. Monin JL, Quéré JP, Monchi M, Petit H, Baleynaud S, Chauvel C, Pop 
C, Ohlmann P, Lelguen C, Dehant P, Tribouilloy C, Guéret P. Low-
gradient aortic stenosis: operative risk stratification and predictors 
for long-term outcome: a multicenter study using dobutamine stress 
hemodynamics. Circulation. 2003;108:319–324. doi: 10.1161/01.
CIR.0000079171.43055.46.
 6. Tribouilloy C, Lévy F, Rusinaru D, Guéret P, Petit-Eisenmann H, 
Baleynaud S, Jobic Y, Adams C, Lelong B, Pasquet A, Chauvel C, Metz 
D, Quéré JP, Monin JL. Outcome after aortic valve replacement for low-
flow/low-gradient aortic stenosis without contractile reserve on dobuta-
mine stress echocardiography. J Am Coll Cardiol. 2009;53:1865–1873. 
doi: 10.1016/j.jacc.2009.02.026.
 7. Herrmann HC, Pibarot P, Hueter I, Gertz ZM, Stewart WJ, Kapadia S, Tuzcu 
EM, Babaliaros V, Thourani V, Szeto WY, Bavaria JE, Kodali S, Hahn RT, 
Williams M, Miller DC, Douglas PS, Leon MB. Predictors of mortality 
and outcomes of therapy in low-flow severe aortic stenosis: a Placement 
of Aortic Transcatheter Valves (PARTNER) trial analysis. Circulation. 
2013;127:2316–2326. doi: 10.1161/CIRCULATIONAHA.112.001290.
 8. Hachicha Z, Dumesnil JG, Bogaty P, Pibarot P. Paradoxical low-flow, 
low-gradient severe aortic stenosis despite preserved ejection fraction 
is associated with higher afterload and reduced survival. Circulation. 
2007;115:2856–2864. doi: 10.1161/CIRCULATIONAHA.106.668681.
 9. Le Ven F, Freeman M, Webb J, Clavel MA, Wheeler M, Dumont É, 
Thompson C, De Larochellière R, Moss R, Doyle D, Ribeiro HB, Urena 
M, Nombela-Franco L, Rodés-Cabau J, Pibarot P. Impact of low flow on 
the outcome of high-risk patients undergoing transcatheter aortic valve 
replacement. J Am Coll Cardiol. 2013;62:782–788. doi: 10.1016/j.
jacc.2013.05.044.
 10. Herrmann S, Störk S, Niemann M, Lange V, Strotmann JM, Frantz S, 
Beer M, Gattenlöhner S, Voelker W, Ertl G, Weidemann F. Low-gradient 
aortic valve stenosis myocardial fibrosis and its influence on function 
and outcome. J Am Coll Cardiol. 2011;58:402–412. doi: 10.1016/j.
jacc.2011.02.059.
 11. Maes F, Boulif J, Piérard S, de Meester C, Melchior J, Gerber B, 
Vancraeynest D, Pouleur AC, Lazam S, Pasquet A, Vanoverschelde 
JL. Natural history of paradoxical low-gradient severe aortic ste-
nosis. Circ Cardiovasc Imaging. 2014;7:714–722. doi: 10.1161/
CIRCIMAGING.113.001695.
 12. Dahl JS, Eleid MF, Pislaru SV, Scott CG, Connolly HM, Pellikka PA. 
Development of paradoxical low-flow, low-gradient severe aortic stenosis. 
Heart. 2015;101:1015–1023. doi: 10.1136/heartjnl-2014-306838.
 13. Mehrotra P, Jansen K, Flynn AW, Tan TC, Elmariah S, Picard MH, Hung J. 
Differential left ventricular remodelling and longitudinal function distin-
guishes low flow from normal-flow preserved ejection fraction low-gradi-
ent severe aortic stenosis. Eur Heart J. 2013;34:1906–1914. doi: 10.1093/
eurheartj/eht094.
 14. Clavel MA, Dumesnil JG, Capoulade R, Mathieu P, Sénéchal M, Pibarot 
P. Outcome of patients with aortic stenosis, small valve area, and low-flow, 
low-gradient despite preserved left ventricular ejection fraction. J Am Coll 
Cardiol. 2012;60:1259–1267. doi: 10.1016/j.jacc.2011.12.054.
 15. Minners J, Allgeier M, Gohlke-Baerwolf C, Kienzle RP, Neumann 
FJ, Jander N. Inconsistent grading of aortic valve stenosis by current 
guidelines: haemodynamic studies in patients with apparently nor-
mal left ventricular function. Heart. 2010;96:1463–1468. doi: 10.1136/
hrt.2009.181982.
 16. Clavel MA, Messika-Zeitoun D, Pibarot P, Aggarwal SR, Malouf J, 
Araoz PA, Michelena HI, Cueff C, Larose E, Capoulade R, Vahanian A, 
Enriquez-Sarano M. The complex nature of discordant severe calcified 









13  Dulgheru et al  Multimodality Imaging in AS 
aortic valve disease grading: new insights from combined Doppler echo-
cardiographic and computed tomographic study. J Am Coll Cardiol. 
2013;62:2329–2338. doi: 10.1016/j.jacc.2013.08.1621.
 17. Ozkan A, Hachamovitch R, Kapadia SR, Tuzcu EM, Marwick TH. 
Impact of aortic valve replacement on outcome of symptomatic patients 
with severe aortic stenosis with low gradient and preserved left ven-
tricular ejection fraction. Circulation. 2013;128:622–631. doi: 10.1161/
CIRCULATIONAHA.112.001094.
 18. Tribouilloy C, Rusinaru D, Maréchaux S, Castel AL, Debry N, Maizel 
J, Mentaverri R, Kamel S, Slama M, Lévy F. Low-gradient, low-flow 
severe aortic stenosis with preserved left ventricular ejection fraction: 
characteristics, outcome, and implications for surgery. J Am Coll Cardiol. 
2015;65:55–66. doi: 10.1016/j.jacc.2014.09.080.
 19. Magne J, Pibarot P, Sengupta PP, Donal E, Rosenhek R, Lancellotti P. 
Pulmonary hypertension in valvular disease: a comprehensive review on 
pathophysiology to therapy from the HAVEC Group. JACC Cardiovasc 
Imaging. 2015;8:83–99. doi: 10.1016/j.jcmg.2014.12.003.
 20. LaBounty TM, Miyasaka R, Chetcuti S, Grossman PM, Deeb GM, Patel 
HJ, Booher A, Patel S, Bach DS. Annulus instead of LVOT diameter im-
proves agreement between echocardiography effective orifice area and 
invasive aortic valve area. JACC Cardiovasc Imaging. 2014;7:1065–1066. 
doi: 10.1016/j.jcmg.2014.03.021.
 21. Kadem L, Dumesnil JG, Rieu R, Durand LG, Garcia D, Pibarot P. Impact 
of systemic hypertension on the assessment of aortic stenosis. Heart. 
2005;91:354–361. doi: 10.1136/hrt.2003.030601.
 22. Briand M, Dumesnil JG, Kadem L, Tongue AG, Rieu R, Garcia D, Pibarot 
P. Reduced systemic arterial compliance impacts significantly on left ven-
tricular afterload and function in aortic stenosis: implications for diagno-
sis and treatment. J Am Coll Cardiol. 2005;46:291–298. doi: 10.1016/j.
jacc.2004.10.081.
 23. Baumgartner H, Stefenelli T, Niederberger J, Schima H, Maurer G. 
“Overestimation” of catheter gradients by Doppler ultrasound in patients 
with aortic stenosis: a predictable manifestation of pressure recovery. J Am 
Coll Cardiol. 1999;33:1655–1661.
 24. Gilon D, Cape EG, Handschumacher MD, Song JK, Solheim J, 
VanAuker M, King ME, Levine RA. Effect of three-dimensional valve 
shape on the hemodynamics of aortic stenosis: three-dimensional echo-
cardiographic stereolithography and patient studies. J Am Coll Cardiol. 
2002;40:1479–1486.
 25. Altiok E, Koos R, Schröder J, Brehmer K, Hamada S, Becker M, Mahnken 
AH, Almalla M, Dohmen G, Autschbach R, Marx N, Hoffmann R. 
Comparison of two-dimensional and three-dimensional imaging tech-
niques for measurement of aortic annulus diameters before transcath-
eter aortic valve implantation. Heart. 2011;97:1578–1584. doi: 10.1136/
hrt.2011.223974.
 26. Garbi M, Chambers J, Vannan MA, Lancellotti P. Valve stress echocar-
diography: a practical guide for referral, procedure, reporting, and clini-
cal implementation of results from the HAVEC group. JACC Cardiovasc 
Imaging. 2015;8:724–736. doi: 10.1016/j.jcmg.2015.02.010.
 27. Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Barón-Esquivias G, 
Baumgartner H, Borger MA, Carrel TP, De Bonis M, Evangelista A, 
Falk V, Lung B, Lancellotti P, Pierard L, Price S, Schäfers HJ, Schuler 
G, Stepinska J, Swedberg K, Takkenberg J, Von Oppell UO, Windecker 
S, Zamorano JL, Zembala M; ESC Committee for Practice Guidelines 
(CPG); Joint Task Force on the Management of Valvular Heart Disease 
of the European Society of Cardiology (ESC); European Association for 
Cardio-Thoracic Surgery (EACTS). Guidelines on the management of val-
vular heart disease (version 2012): the Joint Task Force on the Management 
of Valvular Heart Disease of the European Society of Cardiology (ESC) 
and the European Association for Cardio-Thoracic Surgery (EACTS). Eur 
J Cardiothorac Surg. 2012;42:S1–S44. doi: 10.1093/ejcts/ezs455.
 28. Lancellotti P, Lebois F, Simon M, Tombeux C, Chauvel C, Pierard LA. 
Prognostic importance of quantitative exercise Doppler echocardiogra-
phy in asymptomatic valvular aortic stenosis. Circulation. 2005;112(9 
suppl):I377–I382. doi: 10.1161/CIRCULATIONAHA.104.523274.
 29. Das P, Rimington H, Chambers J. Exercise testing to stratify risk in aortic 
stenosis. Eur Heart J. 2005;26:1309–1313. doi: 10.1093/eurheartj/ehi250.
 30. Rafique AM, Biner S, Ray I, Forrester JS, Tolstrup K, Siegel RJ. Meta-
analysis of prognostic value of stress testing in patients with asymptomatic 
severe aortic stenosis. Am J Cardiol. 2009;104:972–977. doi: 10.1016/j.
amjcard.2009.05.044.
 31. Donal E, Thebault C, O’Connor K, Veillard D, Rosca M, Pierard L, 
Lancellotti P. Impact of aortic stenosis on longitudinal myocardial de-
formation during exercise. Eur J Echocardiogr. 2011;12:235–241. doi: 
10.1093/ejechocard/jeq187.
 32. Maréchaux S, Hachicha Z, Bellouin A, Dumesnil JG, Meimoun P, Pasquet 
A, Bergeron S, Arsenault M, Le Tourneau T, Ennezat PV, Pibarot P. 
Usefulness of exercise-stress echocardiography for risk stratification 
of true asymptomatic patients with aortic valve stenosis. Eur Heart J. 
2010;31:1390–1397. doi: 10.1093/eurheartj/ehq076.
 33. Lancellotti P, Magne J, Donal E, O’Connor K, Dulgheru R, Rosca M, 
Pierard LA. Determinants and prognostic significance of exercise pulmo-
nary hypertension in asymptomatic severe aortic stenosis. Circulation. 
2012;126:851–859. doi: 10.1161/CIRCULATIONAHA.111.088427.
 34. Maréchaux S, Ennezat PV, LeJemtel TH, Polge AS, de Groote P, 
Asseman P, Nevière R, Le Tourneau T, Deklunder G. Left ven-
tricular response to exercise in aortic stenosis: an exercise echo-
cardiographic study. Echocardiography. 2007;24:955–959. doi: 
10.1111/j.1540-8175.2007.00501.x.
 35. Clavel MA, Ennezat PV, Maréchaux S, Dumesnil JG, Capoulade R, 
Hachicha Z, Mathieu P, Bellouin A, Bergeron S, Meimoun P, Arsenault 
M, Le Tourneau T, Pasquet A, Couture C, Pibarot P. Stress echocardiogra-
phy to assess stenosis severity and predict outcome in patients with para-
doxical low-flow, low-gradient aortic stenosis and preserved LVEF. JACC 
Cardiovasc Imaging. 2013;6:175–183. doi: 10.1016/j.jcmg.2012.10.015.
 36. Clavel MA, Burwash IG, Mundigler G, Dumesnil JG, Baumgartner 
H, Bergler-Klein J, Sénéchal M, Mathieu P, Couture C, Beanlands R, 
Pibarot P. Validation of conventional and simplified methods to calculate 
projected valve area at normal flow rate in patients with low flow, low 
gradient aortic stenosis: the multicenter TOPAS (True or Pseudo Severe 
Aortic Stenosis) study. J Am Soc Echocardiogr. 2010;23:380–386. doi: 
10.1016/j.echo.2010.02.002.
 37. Messika-Zeitoun D, Serfaty JM, Brochet E, Ducrocq G, Lepage L, 
Detaint D, Hyafil F, Himbert D, Pasi N, Laissy JP, Iung B, Vahanian A. 
Multimodal assessment of the aortic annulus diameter: implications for 
transcatheter aortic valve implantation. J Am Coll Cardiol. 2010;55:186–
194. doi: 10.1016/j.jacc.2009.06.063.
 38. Jilaihawi H, Doctor N, Kashif M, Chakravarty T, Rafique A, Makar M, 
Furugen A, Nakamura M, Mirocha J, Gheorghiu M, Stegic J, Okuyama 
K, Sullivan DJ, Siegel R, Min JK, Gurudevan SV, Fontana GP, Cheng 
W, Friede G, Shiota T, Makkar RR. Aortic annular sizing for transcath-
eter aortic valve replacement using cross-sectional 3-dimensional trans-
esophageal echocardiography. J Am Coll Cardiol. 2013;61:908–916. doi: 
10.1016/j.jacc.2012.11.055.
 39. Feuchtner G, Plank F, Bartel T, Mueller S, Leipsic J, Schachner T, Müller 
L, Friedrich G, Klauser A, Grimm M, Bonaros N. Prediction of paravalvu-
lar regurgitation after transcatheter aortic valve implantation by computed 
tomography: value of aortic valve and annular calcification. Ann Thorac 
Surg. 2013;96:1574–1580. doi: 10.1016/j.athoracsur.2013.06.049.
 40. Aggarwal SR, Clavel MA, Messika-Zeitoun D, Cueff C, Malouf J, Araoz 
PA, Mankad R, Michelena H, Vahanian A, Enriquez-Sarano M. Sex dif-
ferences in aortic valve calcification measured by multidetector computed 
tomography in aortic stenosis. Circ Cardiovasc Imaging. 2013;6:40–47. 
doi: 10.1161/CIRCIMAGING.112.980052.
 41. Clavel MA, Pibarot P, Messika-Zeitoun D, Capoulade R, Malouf J, 
Aggarval S, Araoz PA, Michelena HI, Cueff C, Larose E, Miller JD, 
Vahanian A, Enriquez-Sarano M. Impact of aortic valve calcification, as 
measured by MDCT, on survival in patients with aortic stenosis: results of 
an international registry study. J Am Coll Cardiol. 2014;64:1202–1213. 
doi: 10.1016/j.jacc.2014.05.066.
 42. Habis M, Daoud B, Roger VL, Ghostine S, Caussin C, Ramadan R, Nottin 
R, Lancelin B, Angel CY, Capderou A, Paul JF. Comparison of 64-slice 
computed tomography planimetry and Doppler echocardiography in the 
assessment of aortic valve stenosis. J Heart Valve Dis. 2007;16:216–224.
 43. Eichenberger AC, Jenni R, von Schulthess GK. Aortic valve pressure gra-
dients in patients with aortic valve stenosis: quantification with velocity-
encoded cine MR imaging. AJR Am J Roentgenol. 1993;160:971–977. 
doi: 10.2214/ajr.160.5.8470612.
 44. Dweck MR, Joshi S, Murigu T, Alpendurada F, Jabbour A, Melina G, 
Banya W, Gulati A, Roussin I, Raza S, Prasad NA, Wage R, Quarto 
C, Angeloni E, Refice S, Sheppard M, Cook SA, Kilner PJ, Pennell 
DJ, Newby DE, Mohiaddin RH, Pepper J, Prasad SK. Midwall fi-
brosis is an independent predictor of mortality in patients with aor-
tic stenosis. J Am Coll Cardiol. 2011;58:1271–1279. doi: 10.1016/j.
jacc.2011.03.064.
 45. Barone-Rochette G, Piérard S, De Meester de Ravenstein C, Seldrum 
S, Melchior J, Maes F, Pouleur AC, Vancraeynest D, Pasquet A, 
Vanoverschelde JL, Gerber BL. Prognostic significance of LGE by CMR 
in aortic stenosis patients undergoing valve replacement. J Am Coll 
Cardiol. 2014;64:144–154. doi: 10.1016/j.jacc.2014.02.612.









14  Dulgheru et al  Multimodality Imaging in AS 
 46. Irkle A, Vesey AT, Lewis DY, Skepper JN, Bird JL, Dweck MR, Joshi 
FR, Gallagher FA, Warburton EA, Bennett MR, Brindle KM, Newby DE, 
Rudd JH, Davenport AP. Identifying active vascular microcalcification 
by (18)F-sodium fluoride positron emission tomography. Nat Commun. 
2015;6:7495. doi: 10.1038/ncomms8495.
 47. Dweck MR, Jenkins WS, Vesey AT, Pringle MA, Chin CW, Malley 
TS, Cowie WJ, Tsampasian V, Richardson H, Fletcher A, Wallace WA, 
Pessotto R, van Beek EJ, Boon NA, Rudd JH, Newby DE. 18F-sodium flu-
oride uptake is a marker of active calcification and disease progression in 
patients with aortic stenosis. Circ Cardiovasc Imaging. 2014;7:371–378. 
doi: 10.1161/CIRCIMAGING.113.001508.
 48. Dweck MR, Jones C, Joshi NV, Fletcher AM, Richardson H, White A, 
Marsden M, Pessotto R, Clark JC, Wallace WA, Salter DM, McKillop G, 
van Beek EJ, Boon NA, Rudd JH, Newby DE. Assessment of valvular 
calcification and inflammation by positron emission tomography in pa-
tients with aortic stenosis. Circulation. 2012;125:76–86. doi: 10.1161/
CIRCULATIONAHA.111.051052.
 49. Jenkins WS, Vesey AT, Shah AS, Pawade TA, Chin CW, White AC, 
Fletcher A, Cartlidge TR, Mitchell AJ, Pringle MA, Brown OS, Pessotto 
R, McKillop G, Van Beek EJ, Boon NA, Rudd JH, Newby DE, Dweck 
MR. Valvular (18)F-fluoride and (18)F-fluorodeoxyglucose uptake 
predict disease progression and clinical outcome in patients with aor-
tic stenosis. J Am Coll Cardiol. 2015;66:1200–1201. doi: 10.1016/j.
jacc.2015.06.1325.
 50. Otto CM, Burwash IG, Legget ME, Munt BI, Fujioka M, Healy NL, Kraft 
CD, Miyake-Hull CY, Schwaegler RG. Prospective study of asymptomatic 
valvular aortic stenosis. Clinical, echocardiographic, and exercise predic-
tors of outcome. Circulation. 1997;95:2262–2270.
 51. Pellikka PA, Sarano ME, Nishimura RA, Malouf JF, Bailey KR, 
Scott CG, Barnes ME, Tajik AJ. Outcome of 622 adults with asymp-
tomatic, hemodynamically significant aortic stenosis during pro-
longed follow-up. Circulation. 2005;111:3290–3295. doi: 10.1161/
CIRCULATIONAHA.104.495903.
 52. Lancellotti P, Rosenhek R, Pibarot P, Iung B, Otto CM, Tornos P, Donal E, 
Prendergast B, Magne J, La Canna G, Piérard LA, Maurer G. ESC work-
ing group on valvular heart disease position paper–heart valve clinics: or-
ganization, structure, and experiences. Eur Heart J. 2013;34:1597–1606. 
doi: 10.1093/eurheartj/ehs443.
 53. Eleid MF, Sorajja P, Michelena HI, Malouf JF, Scott CG, Pellikka PA. 
Flow-gradient patterns in severe aortic stenosis with preserved ejection 
fraction: clinical characteristics and predictors of survival. Circulation. 
2013;128:1781–1789. doi: 10.1161/CIRCULATIONAHA.113.003695.
 54. Lancellotti P, Donal E, Magne J, Moonen M, O’Connor K, Daubert JC, 
Pierard LA. Risk stratification in asymptomatic moderate to severe aortic 
stenosis: the importance of the valvular, arterial and ventricular interplay. 
Heart. 2010;96:1364–1371. doi: 10.1136/hrt.2009.190942.
 55. Clavel MA, Malouf J, Michelena HI, Suri RM, Jaffe AS, Mahoney DW, 
Enriquez-Sarano M. B-type natriuretic peptide clinical activation in aortic 
stenosis: impact on long-term survival. J Am Coll Cardiol. 2014;63:2016–
2025. doi: 10.1016/j.jacc.2014.02.581.
 56. Mohty D, Boulogne C, Magne J, Pibarot P, Echahidi N, Cornu E, Dumesnil 
J, Laskar M, Virot P, Aboyans V. Prevalence and long-term outcome of 
aortic prosthesis-patient mismatch in patients with paradoxical low-flow 
severe aortic stenosis. Circulation. 2014;130(11 suppl 1):S25–S31. doi: 
10.1161/CIRCULATIONAHA.113.007819.









Linda Gillam and Patrizio Lancellotti
Julien Magne, Erwan Donal, Anne Bernard, Khalil Fattouch, Bernard Cosyns, Mani Vannan, 
Raluca Dulgheru, Philippe Pibarot, Partho P. Sengupta, Luc A. Piérard, Raphael Rosenhek,
Heart Valve Clinic International Database (HAVEC) Group
Multimodality Imaging Strategies for the Assessment of Aortic Stenosis: Viewpoint of the
Print ISSN: 1941-9651. Online ISSN: 1942-0080 
Copyright © 2016 American Heart Association, Inc. All rights reserved.
Dallas, TX 75231
is published by the American Heart Association, 7272 Greenville Avenue,Circulation: Cardiovascular Imaging 
doi: 10.1161/CIRCIMAGING.115.004352
2016;9:e004352Circ Cardiovasc Imaging. 
 http://circimaging.ahajournals.org/content/9/2/e004352
World Wide Web at: 
The online version of this article, along with updated information and services, is located on the
 http://circimaging.ahajournals.org/content/suppl/2016/02/10/CIRCIMAGING.115.004352.DC1.html
Data Supplement (unedited) at:
  
 http://circimaging.ahajournals.org//subscriptions/
is online at: Circulation: Cardiovascular Imaging  Information about subscribing to Subscriptions:
  
 http://www.lww.com/reprints
 Information about reprints can be found online at: Reprints:
  
document. Permissions and Rights Question and Answer information about this process is available in the
requested is located, click Request Permissions in the middle column of the Web page under Services. Further
Center, not the Editorial Office. Once the online version of the published article for which permission is being 
 can be obtained via RightsLink, a service of the Copyright ClearanceCirculation: Cardiovascular Imagingin
 Requests for permissions to reproduce figures, tables, or portions of articles originally publishedPermissions:










Suppl 1: Standardized echocardiography report of the HAVEC group  
Parameters Key points 
Body surface area, m² Same formula to estimate body surface area has to be use with each echocardiographic 
study 
Systolic Blood Pressure, mmHg Systematically measured before each echocardiogram 
If high, rescanning is necessary after control of blood pressure values, since it may 
affect gradients and effective orifice area measurements 
2D Echocardiography  
Valve morphology  
 Number of leaflets Tricuspid/Bicuspid/Unknown 
 Degree of calcification Mildly/Moderately/Severely Calcified  
Etiology Calcific/Rheumatic/Congenital/Post-radiotheraphy/Others 
Grading severity  
 Effective AVA, cm² AVA as assessed by the continuity equation 
LV outflow tract diameter and stroke volume index should always be reported to allow 
accurate progression monitoring and classify patients according to the flow-gradient 
relationship  
 Indexed AVA, cm²/m² Indexed AVA should always be performed, especially in small stature or tall patients  
Indexed AVA should be interpreted with caution in obese patients 
 Aortic peak velocity, m/s All echocardiographic windows have to be used in order to allow reporting of 
maximal velocity 
The echocardiographic window that yields the highest value has to be reported for 
accurate progression monitoring 
 Mean transaortic pressure 
gradient, mmHg 
LV geometry and function  
 LV mass index, g/m² Hemodynamically significant AS is virtually always associated with LV 
remodelling/hypertrophy  Relative wall thickness 
 Pattern of LV remodelling Normal LV/LV concentric remodelling/LV concentric hypertrophy/LV eccentric 
hypertrophy 
 LV ejection fraction, % As assessed by biplane Simpson method, stroke volume index obtained by this 
method may be recorded to allow recalculation of effective orifice area 
 Global longitudinal function, % Always report the vendor used for analysis to allow longitudinal comparison  
 Mitral E/A Diastolic function grade/pattern; increased LV filling pressure 
 Mitral E/e’ 
Consequences on LA and pulmonary 
vasculature 
 
 Left atrial volume index, mL/m² Use biplane Simpson’s method 
 Transtricuspid pressure gradient, 
mmHg 
Conclude the possibility/probability of having or not pulmonary hypertension 
 
 Inferior vena cava diameter and 
respiratory changes, mm and % 
 Systolic pulmonary arterial 
pressure, mmHg 
LV hemodynamic load  
 Systemic arterial compliance 
mL/m²/mmHg 
Assessment of arterial load is very important in the understanding of AS 
physiopathology, as it is not an isolated valvular disease, but a complex systemic 
process affecting both the valve and the arterial system  Global afterload, mmHg/mL/m² 
AS: aortic stenosis, AVA: aortic valve area, LV: left ventricle 
 
Suppl 2: Measurement of left ventricular outflow tract diameter by transthoracic 
echocardiography 
Caption: Difference between proximal left ventricular outflow tract (LVOT) diameter (0.5-1cm 
below the aortic cusps (orange arrows # 3 and 4), distal LVOT diameter measured just (2-3 mm) 
below the aortic annulus at the level of the membranous section of the septum (orange #2), and 
the aortic annulus diameter measured at the base of the aortic valve cusps (orange arrow #1)in a 
patient with AS. Note that the presence of septal basal hypertrophy may lead to considerable 
underestimation of LVOT diameter if measured at the proximal level of the LVOT (orange arrow 
#4). It is recommended to use the distal LVOT diameter (arrow #2) or the aortic annulus 







Suppl 3: Underestimation of left ventricle outflow tract diameter by transthoracic 
echocardiography in patients with non-circular outflow tract geometry revealed with 3D 
imaging techniques (3D echocardiography and CT). 
Caption: Patient with an AS and an elliptical left ventricular outflow tract (LVOT) in whom 
measurement of the LVOT diameter in the standard parasternal long-axis view led to an 
underestimation of the effective aortic valve area (AVA) by the continuity equation. 3D imaging 
(Panel D, E and F) reveals the elliptical shape of the LVOT. Note that 2D echocardiographic 
techniques can underestimate the size of the LVOT because only the smallest (sagittal) diameter 
can be measured (Panel A-transthoracic and B-transesophageal). A similar value for the antero-
posterior diameter of the LVOT can be obtained by CT or CMR (Panel C). 3D transthoracic 
echocardiography (Panel D), 3D transesophageal (Panel E) and CT (Panel F) allow measurement 
of the antero-posterior diameter (red arrow) and of the coronal diameter (white arrow) as well as 
direct planimetry of the cross sectional area of the LVOT (red ellipse Panel F). 
 
Suppl. 4: Aortic valve calcium score assessment by multi-slice computed tomography in 
patients with pseudo-severe aortic stenosis (AS) and preserved left ventricular ejection 
fraction (LVEF) (A) and low gradient true severe aortic stenosis and reduced LVEF (AS) 
(B). 
Caption: A) Female patient with low aortic valve calcium load by MSCT-multi-slice computed 
tomography (AVC) pleading for pseudo-severe AS. B) Female patient with high AVC 
confirming the presence of true severe AS. Green areas represent aortic valve calcifications 
(arrows).  
Legend: AVA: aortic valve area; LVEF: left ventricular ejection fraction; MPG: mean pressure 
gradient; SVi: stroke volume index 
 
 
Suppl. 5: Assessment of myocardial fibrosis by contrast enhanced cardiac magnetic 
resonance 
Caption: A) Patient with moderate aortic stenosis and no fibrosis (absence of late gadolinium 
enhancement); B) Patient with severe aortic stenosis and mild fibrosis (red arrow); C) Patient 
with severe aortic stenosis and extensive fibrosis (white arrows); DE) Short-axis midventricular 
unenhanced T1 mapping shows homogenous distribution of the T1 values (A). 15 minutes after 
gadolinium injection at the same location (B), the anteroseptal myocardial values of T1 are 
decreased as compared to the opposite area, with an intramyocardial and subendocardial 
predominance (arrow), figuring increased intramyocardial volume of distribution of the contrast 
agent (fibrosis) 
 
Suppl. 6: 18F-Fluoride PET/CT imaging in aortic stenosis 
Caption: A) Contrast enhanced CT image of the aortic valve demonstrates a try-leaflet aortic 
valve with little calcification visible; B) 18F-Fluoride PET image fused with the CT scans 
demonstrates several areas of increased uptake, indicating regions of calcification activity. 
 Courtesy of Drs. Tania Pawade and Marc Dweck 
 
Suppl. 7: Figure 4: Multimodality imaging use for diagnosis and risk stratification in a 
patient with low flow low gradient AS with preserved left ventricular ejection fraction.   
Caption: Low flow low gradient severe AS with preserved left ventricular ejection fraction 
(LVEF). Note the presence of significant LV hypertrophy with a small LV cavity size (Panel A). 
Careful measurement of LVOT diameter is performed in parasternal long-axis view in mid-
systole, zoomed mode (Panel B). LVEF is preserved but longitudinal systolic dysfunction is 
present (reduced global longitudinal strain (GLS, Panel G). Stroke volume and indexed stroke 
volume are calculated by the Doppler method and confirm the presence of a low flow state 
(Panel C). AVA is calculated by the continuity equation and indicates a severe AS (AVA<1.0 
cm², Panel D), in discordance with the mean gradient, which is below 40 mmHg (Panel D). 
Aortic valve calcium score confirms the presence of a high aortic valve calcium load (Panel E), 
while CMR provides direct planimetry of the anatomic valve area (Panel F) and helps in risk 
stratification by identifying mid-wall fibrosis (red arrows, Panel H). 3D transthoracic 
echocardiography helps to confirm the low-flow state. Note the low 3D stroke volume (Panel I). 
 
